ASF1B and hepatocellular carcinoma: Interestingly, ASF1B was considered to be associated with immunotherapy efficacy in both hepatocellular carcinoma as well as LUAD, however, the correlation between ASF1B expression and the abundance of immune cell infiltration was clearly different in these two cancers.